Conference Reports for NATAP

62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back

Telaprevir at AASLD       AASLD: Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: A 24-Week Treatment Interim Analysis - (11/08/11)   AASLD: Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-based Regimen Regardless of Liver Fibrosis Stage - (11/15/11)   AASLD: Efficacy and Safety of Telaprevir-based Regimens in Cirrhotic Patients with HCV Genotype 1 and Prior Peginterferon/Ribavirin Treatment Failure: Subanalysis of the REALIZE Phase III Study - (11/07/11)   AASLD: Retreatment with Telaprevir/Peg-IFN/RBV after a Short Exposure to Telaprevir in Phase I Studies: Interim Results from a Phase IIIb Rollover Trial (C219) - (11/07/11)   AASLD: Predictors of Virologic Response with Telaprevir-based Combination Treatment in HCV Genotype 1-infected Patients with Prior Peginterferon/ribavirin Treatment Failure: Post-hoc Analysis of the Phase III REALIZE Study - (11/09/11)   AASLD: Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-Based Regimens: Interim Analysis from the EXTEND Study - (11/09/11)   AASLD: VX-222/Telaprevir in Combination With Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 1 HCV Patients Treated for 12 Weeks: ZENITH Study, SVR12 Interim Analysis - (11/09/11)   AASLD: In Null Responders 4 Week Peg/Rbv Lead-In Predicts SVR' - Different Likelihood of Achieving SVR on a Telaprevir-containing Regimen Among Null Responders, Partial Responders and Relapsers Irrespective of Similar Responses after a Peginterferon/Ribavirin 4-week Lead-in Phase: REALIZE Study Subanalysis - (11/09/11)   AASLD: Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR) - (11/07/11) press release   AASLD: Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® - (11/07/11) press release